Massachusetts Patent of the Month – March 2021

Osteosarcoma is the most common malignant bone cancer. Early treatments involved amputation. Current treatments focus on chemotherapy and radiation instead. Targeting molecules important in tumor formation, known as “targeted therapy”, has been an exciting development in cancer treatment in the past ten years. However, no targeted therapy is currently available for osteosarcoma. 3-D Matrix, LTD has designed a possible treatment method which targets the cells that initiate tumor growth.

MicroRNA (miRNA) are known to play important roles in a variety of physiological and pathological processes. Certain miRNA have been discovered to contribute to cancer stem cells (CSC) and tumor-initiating cells (TICs). Antisense oligonucleotides are single stranded RNA that are complementary to a protein coding messenger RNA. The antisense hybridizes with the complementary messenger RNA and blocks its translation. 3-D Matrix’s treatment uses these behaviours to block the formation of tumors. The method involves administering an effective amount of an antisense molecule specific for an miRNA. The miRNA of interest are miR-1, miR-10b, and miR-133a based on discoveries in their roles in tumor initiation. Certain versions of their design are even compatible with standard chemotherapy already applied to osteosarcoma.

About 3-D Matrix, LTD.

3-D Matrix is a medical device company that offers innovative peptide technology, revolutionising the way healthcare professionals manage oozing bleeding during surgery. Headquartered in Tokyo, Japan, 3-D Matrix has expanded across America, Europe, Middle East and Asia. The company collaborates with many researchers, surgeons, healthcare providers and distributors across the world to continually improve on their product.

Are you developing new technology ? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts